PTO/SB/08 Equivalent

INFORMATION DISCLOSUSE STATEMENT BY APPLICANT (Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/063,518
Filing Date	May 1, 2002
First Named Inventor	Goddard, et al.
Art Unit	1642
Examiner	Larry Ronald Helms
Attorney Docket No.	GNE.3230R1C10

Examiner Initials Cite No. Document Number Number - Kind Code (if known) Example: 1,234,567 B1 Document Number Publication Date MM-DD-YYYY Name of Patentee or Applicant Passages or Reference Figures Appear						
-						

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T¹
					,	
				· · · · · · · · · · · · · · · · · · ·		
•	 					
						<u> </u>

	NON PATENT LITERATURE DOCUMENTS	
Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ1
1	LABAER, Joshua. 2003. Letter to the editor: Mining the literature and large datasets. <i>Nature Biotechnology</i> , 21(9):976-977.	
3	LICHTINGHAGEN, et al. 2002. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. European Urology, 42:398-406.	
4	YOUSEF, et al. 2003. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Research, 63:2223-2227.	
	No. 1	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. LABAER, Joshua. 2003. Letter to the editor: Mining the literature and large datasets. Nature Biotechnology, 21(9):976-977. LIAN, et al. 2001. Genomic and proteomic analysis of the myeloid differentiation program. Blood, 98(3):513-524. LICHTINGHAGEN, et al. 2002. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. European Urology, 42:398-406. YOUSEF, et al. 2003. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Research,

2074523:dmb 111605

Examiner Signature	/David Blanchard/	Date Considered	10/24/2006
)—————————————————————————————————————			

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T1 - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)
SHEET 1 OF 2

	P10/SB/08 Equivalent
Application No.	10/063,518
Filing Date	May 1, 2002
First Named Inventor	Goddard, et al.
Art Unit	1643
Examiner	David J. Blanchard SEP 0 5 2006
Attorney Docket No.	GNE.3230R1C10

	U.S. PATENT DOCUMENTS			TO TRADELIST	
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
			·		

			FOREIGN PATE	NT DOCUMENTS		
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	۲
		·	·			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials No. Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ¹	
DB	1	BERNER, et al. 2003. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. <i>Histopathology</i> , 42:546-554.	
	2	BROOKS, et al. 2003. cDNA array identification of genes regulated in rat renal medulla in response to vasopressin infusion. <i>Am. J. Physiol. Renal Physiol.</i> , 284:F218-F228.	
	3	CONRADS, et al. 2005. A combined proteome and microarray investigation of inorganic phosphate-induced pre-osteoblast cells. <i>Molecular & Cellular Proteomics</i> , 4(9):1284-1296.	
	4	CZUPALLA, et al. 2005. Comparative study of proteinand mRNA expression during osteoclastogenesis. <i>Proteomics</i> , 5:3868-3875.	
	5	FUTCHER, et al. 1999. A sampling of the yeast proteome. Molecular and Celular Biology, 19(11):7357-7368.	
	6	GINESTIER, et al. 2002. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. <i>American Journal of Pathology</i> , 161(4):1223-1233.	
	7	GRONBORG, et al. 2006. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. <i>Mol Cell Proteomics</i> , Jan:5(1):157-71. Epub 2005 Oct 8. (ABSTRACT ONLY).	
	8	HOUGHTEN, et al. 1986. Relative importance of position and individual amino acid residues in peptide antigen-antibody interactions: Implications in the mechanism of antigenic drift and antigenic shift. New Approaches to Immunization. Vaccines 86, Cold Spring Harbor Laboratory, p. 21-25.	
V	9	KAWAMOTO, et al. 1996. Expression profiles of active genes in human and mouse livers. Gene, 174(1):151-158.	
DB	10	KING, et al. 2001. Gene expression profile analysis by DNA microarrays. JAMA, 286(18):2280-2288.	

Examiner Signature	/David Blanchard/	Date Considered 10/24/2006
*Examiner: Initial if refi	erence considered, whether or not citation is considered. Include copy of this form with	s in conformance with MPEP 609. Draw line through citation if not next communication to applicant.

T1 - Place a check mark in this area when an English language Translation is attached.

	Application No.	10/063,518
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	May 1, 2002
	First Named Inventor	Goddard, et al.
STATEMENT BY APPLICANT	Art Unit	1643
(Multiple sheets used when necessary)	Examiner	David J. Blanchard
SHEET 2 OF 2	Attorney Docket No.	GNE.3230R1C10

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ¹
DB	11	KWONG, et al. 2005. Synchronous global assessment of gene and protein expression in colorectal cancer progression. <i>Genomics</i> , 86:142-158.	
	12	LEDERMAN, et al. 1991. A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. <i>Molecular Immunology</i> , 28(11):1171-1181.	
	13	LEE, et al. 2000. Importance of replication in microarray gene expression studies: Statistical methods and evidence from repetitive cDNA hybridizations. <i>Proc. Natl. Acad. Sci. USA</i> , 97(18):9834-9839.	
	14	MCGUINESS, et al. 1991. Point mutation in meningococcal por A gene associated with increased endemic disease. The Lancet, 337:514-517.	
	15	MCGUINESS. et al. 1993. Class 1 outer membrane protein of <i>Neisseria meningitides</i> : Epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology. <i>Mol. Microbiology</i> , 7:505-514.	
	16	NAGARAJA, et al. 2006. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: Comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene, 25:2328-2338.	
	17	ODA, et al. 1997. Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours. <i>Virchows Arch</i> , 430:99-105.	
	18	SAGYNALIEV, et al. 2005. Web-based data warehouse on gene expression in human colorectal cancer. Proteomics, 5:3066-3078.	
	19	SAITO-HISAMINATO, et al. 2002. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. <i>DNA Research</i> , 9:35-45.	
	20	STEARNS, et al. 1993. Type IV collagenase (M(r) 72,000) expression in human prostate:benign and malignant tissue. Cancer Res.; 53(4):878-883. (ABSTRACT ONLY)	
	21	SUGG, et al. 1998. Cytoplasmic staining of <i>erb</i> B-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. <i>Clinical Endocrinology</i> , 49:629-637.	
	22	TOLER, et al. 2006. Loss of communication in ovarian cancer. American Journal of Obstetrics and Gynecology, 194:e27-e31.	
	23	WAGHRAY, et al. 2001. Identification of androgen-regulated genes in the prostate cancer cell line LNCaP by serial analysis of gene expression and proteomic analysis. <i>Proteomics</i> , 1:1327-1338.	
\forall	24	WASHBURN, et al. 2003. Protein pathway and complex clustering of correlated mRNA and protein expression analyses in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA, 100(6): 3107-3112.	
DB	25	WILDSMITH, S. E., & Spence, F. J. 2003. Gene expression analysis using microarrays. In J. Crocker & P. G. Murray (Eds.), <i>Molecular Biology in Cellular Pathology</i> (pp. 269-286). West Sussex, England: Wiley.	

2797472:dmb 080106

Examiner Signature	/David Blanchard/	Date Considered	10/24/2006
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T¹ - Place a check mark in this area when an English language Translation is attached.